Press releases

Press releases | March 28, 2016

Inmedix Meets with FDA to Discuss the Development Plan Supporting Commercialization of its ANS Neuroscan™

Seattle, WA – March 28, 2016 – Inmedix, the leader in heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, today announced that the FDA has provided guidance for the required development work that can lead to commercialization for the Inmedix ANS Neuroscan™ diagnostic.

Click below to read the full press release.